Editorial
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Cardiol. Jan 26, 2011; 3(1): 1-9
Published online Jan 26, 2011. doi: 10.4330/wjc.v3.i1.1
Cardiorenal syndromes
Peter A McCullough, Aftab Ahmad
Peter A McCullough, Aftab Ahmad, Department of Medicine, Cardiology Section, St. John Providence Health System, Providence Park Hospital, Novi, MI 48374, United States
Author contributions: All authors contributed equally to this work.
Correspondence to: Peter A McCullough, MD, MPH, Department of Medicine, Cardiology Section, St. John Providence Health System, Providence Park Hospital, Institute, 47601 Grand River Avenue, Suite B-125, Novi, MI 48374, United States. peteramccullough@gmail.com
Telephone: +1-248-4655485 Fax: +1-248-4655486
Received: October 28, 2010
Revised: December 3, 2010
Accepted: December 10, 2010
Published online: January 26, 2011
Abstract

Cardiorenal syndromes (CRS) have been subclassified as five defined entities which represent clinical circumstances in which both the heart and the kidney are involved in a bidirectional injury and dysfunction via a final common pathway of cell-to-cell death and accelerated apoptosis mediated by oxidative stress. Types 1 and 2 involve acute and chronic cardiovascular disease (CVD) scenarios leading to acute kidney injury or accelerated chronic kidney disease. Types 2 and 3 describe acute and chronic kidney disease leading primarily to heart failure, although it is possible that acute coronary syndromes, stroke, and arrhythmias could be CVD outcomes in these forms of CRS. Finally, CRS type 5 describes a simultaneous insult to both heart and kidneys, such as sepsis, where both organs are injured simultaneously. Both blood and urine biomarkers are reviewed in this paper and offer a considerable opportunity to enhance the understanding of the pathophysiology and known epidemiology of these recently defined syndromes.

Keywords: Heart diseases, Kidney diseases, Cardiovascular diseases, Biological biomarkers, Creatinine